Thomas F. Isett
Chief Executive Officer at Transposagen Biopharmaceuticals, Inc.
Net worth: 1 032 $ as of 2024-04-29
Thomas F. Isett active positions
Companies | Position | Start | End |
---|---|---|---|
Transposagen Biopharmaceuticals, Inc.
Transposagen Biopharmaceuticals, Inc. BiotechnologyHealth Technology Transposagen Biopharmaceuticals, Inc. operates as a biotechnology company. Its products and services include piggyBac Reagents, cell engineering services and gene editing reagents & kits. The company was founded by Ostertag M. Eric in 2005 and is headquartered in Lexington, KY. | Chief Executive Officer | 2017-07-31 | - |
iBio CDMO LLC
iBio CDMO LLC BiotechnologyHealth Technology Part of iBio, Inc., iBio CDMO LLC is a company that is advancing its immuno-oncology pipeline of antibody therapeutic candidates against hard-to-drug tumor targets. The company is based in Bryan, TX. The company uses its patented discovery platform, which leverages artificial intelligence to consistently deliver antibody candidates against difficult targets. The company's lead candidate, IBIO-101, stimulates anti-tumor immunity by selectively depleting immunosuppressive TREG cells while sparing tumor cell killing T-Effector cells. iBio is pioneering the next generation of antibody therapeutics, leveraging its artificial intelligence-based and epitope steered antibody discovery platform. The company seeks to partner IBIO-400 to develop a safe and effective subunit vaccine capable of differentiating infected from vaccinated animals. The CEO of the company is Thomas F. Isett. | Chief Executive Officer | - | - |
Chairman | - | - |
Career history of Thomas F. Isett
Former positions of Thomas F. Isett
Companies | Position | Start | End |
---|---|---|---|
IBIO, INC. | Director/Board Member | 2022-10-31 | 2022-11-30 |
Chief Executive Officer | 2020-03-09 | 2022-11-30 | |
Chairman | 2020-03-09 | 2022-10-31 | |
President | 2020-12-17 | - | |
Lonza AG
Lonza AG BiotechnologyHealth Technology Lonza AG engages in the research in as well as development, production, and distribution of chemical products and materials. The firm also carries out investment and lending transactions. The company was founded on December 7, 1897 and is headquartered in Visp, Switzerland. | Corporate Officer/Principal | 2008-12-31 | 2011-12-31 |
BECTON, DICKINSON AND COMPANY | Corporate Officer/Principal | - | 2008-12-31 |
Commence Biologics, Inc. | Chief Executive Officer | - | - |
i.e. Advising LLC | Chief Executive Officer | 2014-12-31 | - |
GE AEROSPACE | Corporate Officer/Principal | - | - |
Training of Thomas F. Isett
Drexel University | Undergraduate Degree |
Statistics
International
United States | 9 |
Switzerland | 2 |
Operational
Chief Executive Officer | 5 |
Corporate Officer/Principal | 3 |
Chairman | 2 |
Sectoral
Health Technology | 6 |
Producer Manufacturing | 2 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 3 |
---|---|
IBIO, INC. | Health Technology |
GE AEROSPACE | Producer Manufacturing |
BECTON, DICKINSON AND COMPANY | Health Technology |
Private companies | 5 |
---|---|
Transposagen Biopharmaceuticals, Inc.
Transposagen Biopharmaceuticals, Inc. BiotechnologyHealth Technology Transposagen Biopharmaceuticals, Inc. operates as a biotechnology company. Its products and services include piggyBac Reagents, cell engineering services and gene editing reagents & kits. The company was founded by Ostertag M. Eric in 2005 and is headquartered in Lexington, KY. | Health Technology |
Lonza AG
Lonza AG BiotechnologyHealth Technology Lonza AG engages in the research in as well as development, production, and distribution of chemical products and materials. The firm also carries out investment and lending transactions. The company was founded on December 7, 1897 and is headquartered in Visp, Switzerland. | Health Technology |
i.e. Advising LLC | |
Commence Biologics, Inc. | |
iBio CDMO LLC
iBio CDMO LLC BiotechnologyHealth Technology Part of iBio, Inc., iBio CDMO LLC is a company that is advancing its immuno-oncology pipeline of antibody therapeutic candidates against hard-to-drug tumor targets. The company is based in Bryan, TX. The company uses its patented discovery platform, which leverages artificial intelligence to consistently deliver antibody candidates against difficult targets. The company's lead candidate, IBIO-101, stimulates anti-tumor immunity by selectively depleting immunosuppressive TREG cells while sparing tumor cell killing T-Effector cells. iBio is pioneering the next generation of antibody therapeutics, leveraging its artificial intelligence-based and epitope steered antibody discovery platform. The company seeks to partner IBIO-400 to develop a safe and effective subunit vaccine capable of differentiating infected from vaccinated animals. The CEO of the company is Thomas F. Isett. | Health Technology |
- Stock Market
- Insiders
- Thomas F. Isett
- Experience